Literature DB >> 34097159

Breast Cancer Risk and Screening in Transgender Persons: A Call for Inclusive Care.

Callisia N Clarke1, Chandler S Cortina2, Oluwadamilola M Fayanju3, Lesly A Dossett4, Fabian M Johnston5, Sandra L Wong6.   

Abstract

The Society of Surgical Oncology is committed to reducing health disparities adversely affecting sexual and gender minorities. Transgender persons represent a socially disadvantaged group who frequently experience discrimination and receive disparate care, resulting in suboptimal cancer outcomes. The rate of breast cancer development in transgender individuals differs from rates observed in their cisgender counterparts, however there is little evidence to quantify these differences and guide evidence-based screening and prevention. There is no consensus for breast cancer screening guidelines in transgender patients. In this review, we discuss barriers to equitable breast cancer care, risk factors for breast cancer development, and existing data to support breast cancer screening in transgender men and women.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2021        PMID: 34097159     DOI: 10.1245/s10434-021-10217-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  Cancer screening rates among transgender adults: Cross-sectional analysis of primary care data.

Authors:  Tara Kiran; Sam Davie; Dhanveer Singh; Sue Hranilovic; Andrew D Pinto; Alex Abramovich; Aisha Lofters
Journal:  Can Fam Physician       Date:  2019-01       Impact factor: 3.275

  1 in total
  2 in total

1.  Transgender and Non-binary Persons in Contemporary Oncology Randomized Clinical Trials.

Authors:  Enrique O Martinez; Micah Rubin; Tessa Miller; Chandler S Cortina
Journal:  Ann Surg Oncol       Date:  2022-08-23       Impact factor: 4.339

2.  Disparities in Cancer Care: Educational Initiatives.

Authors:  Monica Morrow; Lisa A Newman
Journal:  Ann Surg Oncol       Date:  2022-01-31       Impact factor: 4.339

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.